Antiviral Drugs Market to Experience 3.73% CAGR through 2032 Due to Increasing Prevalence of Viral Diseases

The global antiviral drugs market is projected to grow from USD 49.8 billion in 2022 to USD 71.1 billion by 2032, with a compound annual growth rate (CAGR) of 3.73% during the forecast period. This growth can be attributed to several factors, including the increasing prevalence of viral infections such as HIV, hepatitis, and influenza. Government initiatives, such as the U.S. “Ending the HIV Epidemic” plan, aim to reduce HIV infections and enhance diagnosis rates, significantly boosting market growth​.

Pharmaceutical companies are heavily investing in research and development to create novel antiviral drugs with improved efficacy and fewer side effects. Innovations in drug development and the discovery of new therapeutic targets are expanding treatment options for healthcare providers. Additionally, public-private partnerships and collaborations are playing a crucial role in advancing antiviral drug discovery and ensuring their accessibility​.

However, the market faces challenges, including the high cost of antiviral drugs and the development of drug-resistant viral strains. The lengthy and expensive process of developing new drugs also poses a significant barrier. Furthermore, the market’s growth is restrained by the limited availability of broad-spectrum antiviral drugs and the increasing emphasis on preventive measures such as vaccinations​.

Recent developments in the market include the introduction of innovative drugs and vaccines. For example, Roche’s Xofluza has been approved for advanced influenza treatment, and Gilead’s Veklury has been introduced for pediatric COVID-19 patients. These advancements highlight the ongoing efforts to enhance antiviral treatment options and address unmet medical needs​.

Key Takeaways

• The antiviral drugs market is expected to reach USD 71.1 billion by 2032, growing from USD 49.8 billion in 2022.
• The market is projected to grow at a CAGR of 3.73% from 2023 to 2032.
• In 2022, the combination drug class segment generated the highest revenue in the antiviral drugs market.
• The human immune deficiency virus segment is anticipated to have the highest market share for disease indication.
• The hospital pharmacy segment dominates the distribution channel and is expected to grow at a significant CAGR.
• North America held the largest market share at 32% in 2022.
• Europe accounted for a revenue share of 20.7% in the antiviral drugs market in 2022.
• The WHO reports millions of people worldwide live with HIV, with many deaths attributed to the virus.
• The U.S. has a significant prevalence of infections, including HIV.

Get Sample PDF Report: https://market.us/report/antiviral-drugs-market/request-sample/

Antiviral Drugs Market Key Segments

By Drug Class

• Polymerase Inhibitors
• Protease Inhibitors
• Integrase Inhibitors
• Reverse Transcriptase Inhibitor
• Combination Drug

By Disease Indication

• Hepatitis
• Human Immuno Deficiency Virus(HPV)
• Influenza
• others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Key Regions

• North America (The US, Canada, Mexico)
• Western Europe (Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, Rest of Western Europe)
• Eastern Europe (Russia, Poland, The Czech Republic, Greece, Rest of Eastern Europe)
• APAC (China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Rest of APAC)
• Latin America (Brazil, Colombia, Chile, Argentina, Costa Rica, Rest of Latin America)
• Middle East & Africa (Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, Rest of MEA)

Buy Directly: https://market.us/purchase-report/?report_id=97163

Key Players Analysis

Gilead Sciences is a leading biopharmaceutical company specializing in antiviral drugs, particularly for HIV, hepatitis B, hepatitis C, and COVID-19. The company has developed significant treatments such as Veklury (remdesivir) for COVID-19 and Biktarvy for HIV, which has expanded indications to treat patients with resistant HIV strains. Gilead continues to innovate with treatments like Sunlenca (lenacapavir), a long-acting HIV treatment administered twice yearly. Their research and development pipeline remains robust, focusing on person-centered biomedical innovations to address evolving global health needs​.

AbbVie is a global biopharmaceutical company known for its strong presence in the antiviral drug market. The company’s antiviral portfolio includes treatments for HIV and hepatitis C. AbbVie’s HIV drugs, such as Kaletra, have been pivotal in managing the disease. Additionally, AbbVie has developed a leading hepatitis C regimen, Mavyret, which is highly effective across multiple genotypes of the virus. Their ongoing research aims to address unmet medical needs in viral diseases, emphasizing long-term therapeutic efficacy and patient accessibility.

GlaxoSmithKline is a major player in the antiviral drugs sector, focusing on treatments for HIV, respiratory viruses, and herpes. GSK has developed several cornerstone HIV treatments through its ViiV Healthcare joint venture, including Tivicay (dolutegravir) and Triumeq (dolutegravir/abacavir/lamivudine). The company also markets Shingrix, a vaccine for shingles, which is crucial for preventing complications from the herpes zoster virus. GSK continues to invest in innovative antiviral therapies and vaccines, aiming to expand its impact on global health.

Merck is renowned for its antiviral research and development, particularly in the HIV and hepatitis C domains. The company’s portfolio includes key HIV treatments such as Isentress (raltegravir) and investigational drugs like islatravir. Merck’s ongoing collaboration with Gilead on lenacapavir highlights its commitment to innovative, long-acting HIV treatments. In hepatitis C, Merck’s Zepatier has been a crucial therapy, providing effective treatment options for diverse patient populations. Merck’s research aims to advance antiviral therapies with a focus on efficacy and safety​.

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is prominent in the antiviral market with significant contributions to HIV treatment. Janssen developed the first single-tablet HIV regimen, Complera, and continues to advance HIV care with drugs like Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide). Their research extends to other viral diseases, including hepatitis B and respiratory viruses, with a strong emphasis on developing innovative, patient-friendly therapies. Janssen’s commitment to improving viral treatment outcomes is reflected in its extensive clinical research and development efforts.

Antiviral Drugs Market Key Players:

• Gilead Sciences Inc.
• AbbVie Inc.
• GlaxoSmithKline
• Merck& C.O. Inc.
• Jannssen Pharmaceuticals Inc.
• Bristol- Meyrs Squibb Company
• Mylan N. V.
• Novartis AG
• AstraZeneca
• Pfizer Inc.
• Cipla Inc.
• Johnson & Johnson Services Inc.
• Aurobindo Pharma
• Merck MRK
• Reddy Laboratories Limited
• Hoffmann-La Roche Ltd.
• Altesa Biosciences Inc.
• Other Key Players

Antiviral Drugs Market Report Scope >> Market Value (2023): USD 49.8 Billion || Forecast Revenue (2033): USD 71.1 Billion || CAGR (2024-2033): 3.7% || Base Year Estimation: 2023 || Historic Period: 2019-2022 || Forecast Period: 2024-2033.

Inquire More about report: https://market.us/report/antiviral-drugs-market/#inquiry

About Market.US

Market.US is renowned for its comprehensive market research and analysis, providing customized and syndicated reports to a global clientele. Specializing in a variety of sectors, they offer strategic insights and detailed market forecasts, assisting businesses in making informed decisions. With a focus on innovation and accuracy, Market.US supports clients in over 126 countries, and maintains a strong repeat customer rate, underscoring their commitment to quality and client satisfaction. Their team excels in delivering exceptional research services, ensuring that no detail is overlooked in any target market.

Contact Details
Market.us (Powered By Prudour Pvt. Ltd.)
Contact No: +1 718 618 4351.
Email: inquiry@market.us
Blog: https://medicalmarketreport.com/

View More Trending Reports

Diabetes Treatment Devices Market Will Reach USD 17,599 Million By 2032

Preclinical CRO Market Will Increase USD 10.5 Billion By 2032

Diagnostics Imaging Market Size Set To Reach USD 54.6 Billion By 2032

Immune Thrombocytopenia Market Will Increase USD 3.4 Billion By 2032

Home Healthcare Market Forecasted To Attain USD 797.8 Billion By 2033, Showcasing A 8.2% CAGR